−0.85 (−4.37%) TodayNov 4, 10:45 AM ET
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
No direct coverage yet · Showing articles that mention NVCT
GlobeNewswire Inc.
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026Nuvectis Pharma announced it will host a conference call on November 4, 2026 at 8:00 AM ET to discuss Q3 2026 business progress and financial results. The clinical-stage biopharmaceutical company is focused on developing therapies for complement-related conditions and oncology, with lead candidate NXP100 (ciprocopan) recently approved in China for PNH treatment.
Headlines open the publisher's site.
